Objective： To evaluate the efficacy of ifosfamide and etoposide （VP-16） in patients with small cell lung cancer （SCLC）, and investigate the correlation between microvessel count （MVC） in tumor and chemotherapeu...Objective： To evaluate the efficacy of ifosfamide and etoposide （VP-16） in patients with small cell lung cancer （SCLC）, and investigate the correlation between microvessel count （MVC） in tumor and chemotherapeutic sensitivity. Methods： Forty-one consecutive cases of SCLC received chemotherapy of ifosfamide plus VP-16, and underwent investigation retrospectively. Immunohistochemistry using anti-human blood type H monoclonal antibody was conducted and MVC was recorded under light microscope. Results： There were 27 limited-disease and 14 extensive-disease patients. The overall response rate was 92.7% （38/41） with 28 cases （68.3%） of complete response （CR）, 10 （24.4%） with partial response （PR）, 3 （7.3%） with progressive disease （PD）. The 1-, 2-, 3-, and 5-year survival rates were 68.3% （28/41）, 48.3% （20/41）, 23.7% （9/38） and 11.1% （3/27）, respectively, with the median survival of 26.8 months. The principal toxicities were grade 3-4 neutropenia in 8 cases （19.5%）, grade 3-4 thrombocytopenia in 6 cases （14.6%）, mild liver toxicity in 7 cases （17.0%） and mild renal function damage in 4 cases （9.8%）. The mesenchymal vasculature was clearly visualized, with the mean value of 34.7 under each high microscopic power field. Of SCLC with more MVC （n=26）, CR accounted for 84.6%; while in cancers with less MVC （n=l 5）, CR took up 40.0%, with significant difference （P〈0.05）. Conclusion： Administrating ifosfamide and VP-16 is in accordance with the biological features of SCLC and results in beneficial results as well as acceptable side effects. The MVC is positively correlated with the chemotherapeutic sensitivity, and serves as a vital factor contributing to chemosensitivity.展开更多
程序性细胞死亡因子5(programmed celldeath5,PDCD5)在多种肿瘤细胞中表达明显降低。携带pdcd5基因的靶向增殖型腺病毒SG611-pdcd5对白血病细胞具有杀伤作用,对正常细胞具有相对保护作用。本研究旨在观察联合应用SG611-pdcd5与低剂量化...程序性细胞死亡因子5(programmed celldeath5,PDCD5)在多种肿瘤细胞中表达明显降低。携带pdcd5基因的靶向增殖型腺病毒SG611-pdcd5对白血病细胞具有杀伤作用,对正常细胞具有相对保护作用。本研究旨在观察联合应用SG611-pdcd5与低剂量化疗药物依托泊甙(etoposide,VP-16)对白血病细胞系K562的作用。以不同浓度梯度的药物或不同感染复数(multiplicity of infection,MOI)的病毒液作用于K562细胞,培养48小时后用MTT法检测细胞存活率。结果表明,与SG611-pdcd5(MOI=40)或VP-16(0.5μg/ml)单独作用组相比,SG611-pdcd5(MOI=40)+VP-16(0.5μg/ml)组细胞存活率明显降低(p均<0.05),分别为(59.45±4.12)%、(82.91±3.41)%及(42.00±5.75)%。SG611-pdcd5与VP-16的协同作用强于PDCD5蛋白或携带pdcd5基因的非增殖型腺病毒Ad-pdcd5与VP-16的协同作用(p均<0.05);VP-16浓度为4.0μg/ml时,VP-16+SG611-pdcd5(MOI=40)组、VP-16+proPDCD5(40μg/ml)组及VP-16+Ad-pdcd5(MOI=80)组细胞存活率分别为(37.09±1.89)%、(52.36±1.64)%及(73.64±4.33)%。结论:SG611-pdcd5具有促进低剂量VP-16杀伤K562细胞的作用,二者联合可增强对白血病细胞的杀伤作用。展开更多
基金This work was supported by a grant from the Education Department of P.R.China (No. 2004[527]).
文摘Objective： To evaluate the efficacy of ifosfamide and etoposide （VP-16） in patients with small cell lung cancer （SCLC）, and investigate the correlation between microvessel count （MVC） in tumor and chemotherapeutic sensitivity. Methods： Forty-one consecutive cases of SCLC received chemotherapy of ifosfamide plus VP-16, and underwent investigation retrospectively. Immunohistochemistry using anti-human blood type H monoclonal antibody was conducted and MVC was recorded under light microscope. Results： There were 27 limited-disease and 14 extensive-disease patients. The overall response rate was 92.7% （38/41） with 28 cases （68.3%） of complete response （CR）, 10 （24.4%） with partial response （PR）, 3 （7.3%） with progressive disease （PD）. The 1-, 2-, 3-, and 5-year survival rates were 68.3% （28/41）, 48.3% （20/41）, 23.7% （9/38） and 11.1% （3/27）, respectively, with the median survival of 26.8 months. The principal toxicities were grade 3-4 neutropenia in 8 cases （19.5%）, grade 3-4 thrombocytopenia in 6 cases （14.6%）, mild liver toxicity in 7 cases （17.0%） and mild renal function damage in 4 cases （9.8%）. The mesenchymal vasculature was clearly visualized, with the mean value of 34.7 under each high microscopic power field. Of SCLC with more MVC （n=26）, CR accounted for 84.6%; while in cancers with less MVC （n=l 5）, CR took up 40.0%, with significant difference （P〈0.05）. Conclusion： Administrating ifosfamide and VP-16 is in accordance with the biological features of SCLC and results in beneficial results as well as acceptable side effects. The MVC is positively correlated with the chemotherapeutic sensitivity, and serves as a vital factor contributing to chemosensitivity.
文摘程序性细胞死亡因子5(programmed celldeath5,PDCD5)在多种肿瘤细胞中表达明显降低。携带pdcd5基因的靶向增殖型腺病毒SG611-pdcd5对白血病细胞具有杀伤作用,对正常细胞具有相对保护作用。本研究旨在观察联合应用SG611-pdcd5与低剂量化疗药物依托泊甙(etoposide,VP-16)对白血病细胞系K562的作用。以不同浓度梯度的药物或不同感染复数(multiplicity of infection,MOI)的病毒液作用于K562细胞,培养48小时后用MTT法检测细胞存活率。结果表明,与SG611-pdcd5(MOI=40)或VP-16(0.5μg/ml)单独作用组相比,SG611-pdcd5(MOI=40)+VP-16(0.5μg/ml)组细胞存活率明显降低(p均<0.05),分别为(59.45±4.12)%、(82.91±3.41)%及(42.00±5.75)%。SG611-pdcd5与VP-16的协同作用强于PDCD5蛋白或携带pdcd5基因的非增殖型腺病毒Ad-pdcd5与VP-16的协同作用(p均<0.05);VP-16浓度为4.0μg/ml时,VP-16+SG611-pdcd5(MOI=40)组、VP-16+proPDCD5(40μg/ml)组及VP-16+Ad-pdcd5(MOI=80)组细胞存活率分别为(37.09±1.89)%、(52.36±1.64)%及(73.64±4.33)%。结论:SG611-pdcd5具有促进低剂量VP-16杀伤K562细胞的作用,二者联合可增强对白血病细胞的杀伤作用。
